Tesla's Downfall is Near…. Here's The Next Big Thing
This Tech Giant is About to Rock the Electric Vehicle Market and Take Over Tesla.

Click Here to see which company is secretly destroying TESLA.
Learn more.

GUD Insider Trading (Knight Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$326,566.00
Insider Selling (Last 12 Months): C$0.00

Knight Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Knight Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Knight Therapeutics Share Price & Price History

Current Price: C$5.43
Price Change: Price Decrease of -0.03 (-0.55%)
As of 09/24/2021 01:00 AM ET

This chart shows the closing price history over time for GUD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The “Tech Royalty” Retirement Plan Can Help You Live Like Royalty
For the first time ever, a new type of tech investment allows you to collect ongoing income. One former Wall Street insider calls them, “Tech Royalties.”

And new “Tech Royalty” savings accounts allow you to collect as much as 8%... 12%... and even 17% or more.
Find out why “Tech Royalties” may be the best asse

Knight Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/20/2021Arvind UtchanahSenior OfficerBuy600C$5.20C$3,120.009,913
8/23/2021Jonathan Ross GoodmanDirectorBuy4,300C$5.36C$23,048.00631,788
8/18/2021Jonathan Ross GoodmanDirectorBuy18,000C$5.39C$97,020.00609,488
7/14/2021Jonathan Ross GoodmanDirectorBuy18,000C$5.30C$95,400.00591,488
7/2/2021Jonathan Ross GoodmanDirectorBuy18,000C$5.24C$94,320.00555,488
5/25/2021Jonathan Ross GoodmanDirectorBuy2,400C$5.25C$12,600.00502,361
1/6/2021Long Zone Holdings Inc. InsiderBuy200C$5.29C$1,058.0021,656,133
7/11/2019Robert Nathaniel LandeDirectorBuy20,000C$7.52C$150,300.0045,392
6/21/2019Long Zone Holdings Inc. InsiderBuy12,000C$7.59C$91,080.0021,633,433
5/21/2019Long Zone Holdings Inc. InsiderBuy10,000C$7.39C$73,900.0021,621,433
4/4/2019Jonathan Ross GoodmanDirectorBuy3,600C$7.38C$26,568.00444,320
See Full Table
Insider Selling at Knight Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Knight Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Knight Therapeutics (TSE:GUD)

Knight Therapeutics logo
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer. The company also provides Burinex, for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome; PROBUPHINE, to treat opioid addiction; and MOVANTIK for the treatment of opioid-induced constipation. In addition, it offers Vidaza to treat myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven to treat advanced or metastatic breast cancer; Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma; Ladevina to treat multiple myeloma; Zyvalix for metastatic prostate cancer; Karfib to treat relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; AmBisome and Cresemba to treat fungal infection; and Impavido for leishmaniasis. Further, the company provides Ursofalk to treat biliary cirrhosis; Salofalk for ulcerative colitis; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Read More on Knight Therapeutics

Today's Range

Now: C$5.43
Low: C$5.40
High: C$5.53

50 Day Range

MA: C$5.29
Low: C$5.04
High: C$5.60

52 Week Range

Now: C$5.43
Low: C$4.88
High: C$5.97


236,700 shs

Average Volume

318,906 shs

Market Capitalization

C$668.44 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Knight Therapeutics?

Knight Therapeutics' top insider shareholders include:
  1. Long Zone Holdings Inc (Insider)
  2. Jonathan Ross Goodman (Director)
  3. Arvind Utchanah (Senior Officer)
Tesla's Downfall is Near…. Here's The Next Big Thing
This Tech Giant is About to Rock the Electric Vehicle Market and Take Over Tesla.

Click Here to see which company is secretly destroying TESLA.
Learn more.